MCM
LGND icon

MAI Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

MAI Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$937K Sell
2,963
-969
-25% -$228K ﹤0.01% 1010
2026
Q1 		$785K Sell
3,932
-1,226
-24% -$243K ﹤0.01% 853
2025
Q4 		$975K Buy
+5,158
New +$991K 0.01% 742
2025
Q3 		– Sell
-12
Closed -$1.36K – 3993
2025
Q2 		$1.36K Buy
+12
New +$1.28K ﹤0.01% 3534

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's LGND Position: Q2 2026 in Review

MAI Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 25% in Q2 2026, selling an estimated $228K and leaving 2,963 shares worth $937K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

MAI Capital Management first reported a position in LGND in Q2 2025 and has held it in 4 quarters since. The position peaked at $975K in Q4 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • MAI Capital Management held 2,963 shares of Ligand Pharmaceuticals worth $937K as of Q2 2026.
  • MAI Capital Management sold 969 Ligand Pharmaceuticals shares in Q2 2026, an estimated $228K.
  • Ligand Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1010 holding.
  • MAI Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • MAI Capital Management's Ligand Pharmaceuticals position peaked at $975K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.